Wild type p53 function in p53^Y220C mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence.

ABSTRACT:

Background

Tumor suppressor p53 protein is frequently mutated in a large majority of cancers. These mutations induce local or global changes in protein structure thereby affecting its binding to DNA. The structural differences between the wild type and mutant p53 thus provide an opportunity to selectively target mutated p53 harboring cancer cells. Restoration of wild type p53 activity in mutants using small molecules that can revert the structural changes have been considered for cancer therapeutics.

Methods

We used bioinformatics and molecular docking tools to investigate the structural changes between the wild type and mutant p53 proteins (p53^V143A, p53^R249S, p53^R273H and p53^Y220C) and explored the therapeutic potential of Withaf

SUBMITTER: Sundar D 

PROVIDER: S-EPMC6390572 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature